Omega-3 and kidney disease: the senescence link nobody was looking for

The pattern: a thirty-year mixed-RCT history

Fish oil and the kidney have a complicated relationship. The earliest randomized data in diabetic nephropathy (1996) showed essentially no effect on albuminuria, glomerular filtration rate, or blood pressure. Trials in IgA nephropathy through the late 1990s and 2000s ran the other way — modest proteinuria reductions, sometimes a slower slope of kidney decline. Then came the 2019 VITAL-DKD trial in JAMA: 1,312 adults with type 2 diabetes randomized to 1 g/day of EPA + DHA or placebo for five years. Change in eGFR from baseline: -12.2 mL/min/1.73 m² on omega-3 versus -13.1 on placebo. A 0.9 mL/min difference with a confidence interval crossing zero². The trialists concluded the findings did not support omega-3 for preserving kidney function in type 2 diabetes.

That is the standard framing — and it is the framing that has kept omega-3 out of nephrology guidelines. But it leaves a problem. A 2023 BMJ pooled analysis of 19 prospective cohorts (25,570 participants, weighted median follow-up 11.3 years) found that people in the highest fifth of seafood-derived omega-3 biomarker levels had a 13 percent lower risk of developing CKD over the next decade compared with the lowest fifth (relative risk 0.87, 95% CI 0.80–0.96, p=0.005). Plant-derived alpha-linolenic acid (ALA) showed no association either way¹. The signal is real and it is specific — to marine, long-chain omega-3, and to the upstream stage of the disease.

The cohort signal and the trial nulls are not the contradiction they look like. They are almost certainly telling two different stories about two different stages of disease — and a 2025 mechanism paper, paired with a quietly important 2021 transplant substudy, finally offers a unifying explanation. The signal omega-3 pulls is upstream of the standard kidney function endpoint everyone has been measuring.

The senescence mechanism — what changed in 2025

Kidney aging is increasingly understood as an accumulation of senescent cells. Senescence is a permanent cell-cycle arrest that cells enter in response to damage, oxidative stress, or replicative exhaustion. The cells don’t die — they sit in tissue and secrete a characteristic mix of inflammatory cytokines, chemokines, growth factors, and matrix-remodeling enzymes called the senescence-associated secretory phenotype, or SASP. The SASP recruits immune cells, activates fibroblasts, and drives the fibrotic scarring that defines progressive chronic kidney disease⁹. In experimental kidney disease models — and increasingly in human biopsies — the senescent-cell burden correlates tightly with disease severity¹¹.

Marine omega-3 fatty acids (EPA and DHA) get incorporated into cell membranes and serve as substrate for a family of specialized pro-resolving lipid mediators: resolvins, protectins, and maresins. These molecules don’t suppress inflammation the way NSAIDs do — they actively switch the immune response from attack to resolution. They shorten neutrophil lifespan in damaged tissue, reprogram macrophages from pro-inflammatory M1 toward pro-resolving M2, and shut down the inflammatory feed-forward loops that drive chronic tissue damage⁸. In a 2025 mouse model of unilateral ureteral obstruction (a standard CKD model), dietary omega-3 PUFAs reduced macrophage activation and infiltration in the kidney by targeting the JAG1-NOTCH1/2 signaling pathway and down-regulating the MCP-1 chemokine and its CCR2 receptor. The result was less fibroblast activation, less extracellular matrix deposition, and slower progression of renal fibrosis⁷.

The human bridge is the 2021 ORENTRA substudy. Kidney transplant recipients — a population with rapidly accumulating graft senescence and elevated SASP — were randomized to 2.6 g/day of marine omega-3 versus olive oil placebo for 44 weeks. The omega-3 arm showed reduced plasma levels of multiple SASP markers: granulocyte colony-stimulating factor, interleukin 1α, macrophage inflammatory protein 1α, and the matrix metalloproteinases MMP-1 and MMP-13⁶. This was a post-hoc analysis with 66 patients per arm — small, exploratory, not yet replicated. But it is the first human data showing omega-3 supplementation moves SASP-associated biomarkers in the right direction in a kidney population.

Put the two findings together and a coherent picture emerges. Omega-3 is not a kidney function drug. It is a senescence-modulating signal that operates upstream of the fibrotic cascade. That is consistent with the cohort data (where the relevant window is decades of background exposure before disease emerges) and consistent with the trial nulls (where 12-month eGFR change in already-damaged kidneys is the wrong yardstick for a slow, upstream-biased intervention).

Omega-3 is not a kidney-function drug. It is a senescence-modulating signal that operates upstream of the fibrotic cascade. The big trials were measuring the wrong thing.

The trials, sorted by what they actually measured

Once the proteinuria signal and the eGFR signal are separated, the literature becomes much more legible. Different outcomes, different populations, different effect sizes.

Proteinuria in diabetic nephropathy. A 2020 PLoS ONE meta-analysis of 10 randomized trials (344 participants) found that omega-3 supplementation reduced proteinuria in type 2 diabetes when the intervention ran at least 24 weeks (standardized mean difference -0.30, 95% CI -0.58 to -0.02, p=0.04). The effect was specific to type 2 diabetes — type 1 showed no significant change — and the duration threshold matters. Short trials missed it⁴. An earlier 2017 meta of 9 RCTs (444 CKD patients, not all diabetic) found the same pattern: lower proteinuria risk (SMD -0.31, 95% CI -0.53 to -0.10, p=0.004) but no statistically detectable change in serum creatinine clearance or eGFR over the trial window⁵.

End-stage kidney disease and cardiovascular mortality. The 2020 Saglimbene meta-analysis (60 trials, 4,129 participants) is the most rigorous synthesis to date. The bottom line, in the authors’ own words: low-to-very-low certainty evidence suggests omega-3 supplementation reduces cardiovascular death in hemodialysis patients (RR 0.45, 95% CI 0.23–0.89) and reduces progression to end-stage kidney disease in pre-dialysis CKD (RR 0.30, 95% CI 0.09–0.98). Effects on all-cause mortality, acute transplant rejection, and allograft loss were null³. Two qualifiers matter: median follow-up was only six months (almost certainly too short to detect a senescence-mediated effect), and the certainty grade is explicitly low.

eGFR in established type 2 diabetes. VITAL-DKD. Five years, 1 g/day, no signal². The dose was modest by interventional standards (the REDUCE-IT cardiovascular trial used 4 g/day of EPA), and the population already had baseline eGFR around 86 mL/min/1.73 m² — well above the senescence-dominant stage of disease. VITAL-DKD is the strongest single piece of evidence that 1 g/day doesn’t move the eGFR needle in this population. It is not strong evidence that omega-3 doesn’t do anything.

Cardiometabolic and oxidative stress markers. A 2021 BMC Nephrology meta-analysis of 13 RCTs found omega-3 supplementation in CKD significantly reduced total cholesterol, triglycerides, and the oxidative damage marker malondialdehyde, and significantly raised the antioxidant enzymes superoxide dismutase and glutathione peroxidase. Blood pressure and LDL did not change¹⁰. None of these are kidney function endpoints, but they are biologically congruent with the resolvin pathway and the senescence story.

The compressed read: the evidence for proteinuria reduction in type 2 diabetic nephropathy is real and probably actionable. The evidence for slowing eGFR decline in already-established CKD is weak and inconsistent. The cohort evidence for primary prevention (lower incident CKD risk over a decade) is the strongest signal of all, and it is invisible in the short-window supplementation trials. That asymmetry is the heart of the story.

A practical, tiered framework

Because this is a clinical kidney-disease topic and not a wellness optimization topic, the framing has to stay tight. None of this is medical advice. Anyone with diagnosed CKD should be discussing omega-3 with their nephrologist, not a website. That said, the trial data translate into three honest tiers.

Foundational tier (general population, primary prevention). The pooled cohort data support a habitual dietary intake of marine omega-3 from food — two servings of oily fish per week is the conventional cardiology target and is sufficient to populate the higher biomarker quintiles in the BMJ pooled analysis¹. Plant-derived ALA from flax, chia, or walnut does not appear to substitute for marine EPA/DHA for this specific outcome; the cohort signal was marine-only¹. Supplementation at 1–2 g/day combined EPA + DHA is a reasonable food substitute for people who don’t eat fish.

Research-curious tier (early CKD or proteinuria, with clinician oversight). The meta-analyses supporting proteinuria reduction in type 2 diabetic nephropathy used sustained dosing of 2–4 g/day combined EPA + DHA for at least 24 weeks⁴. This is well above general-population intake and well below VITAL-DKD’s 1 g/day. It is also above the dose at which clinically meaningful antiplatelet effects start to appear (see grey areas below). This is a conversation with the prescribing clinician, not a self-experiment — especially because most CKD patients are already on RAAS inhibitors and antiplatelet therapy that compound the bleeding-risk profile.

Experimental tier (hemodialysis or transplant population). The cardiovascular-mortality signal in dialysis patients³ and the SASP-modulation signal in transplant recipients⁶ are both interesting and both based on low-certainty evidence. Doses in these trials ranged from 1.8–2.6 g/day combined EPA + DHA. Neither population should be modifying anything without explicit nephrology input — anticoagulation interactions, fluid balance, and transplant immunosuppression timing all matter.

For the broader picture on how supplements interact at the cellular level with senescence and aging, the GlyNAC aging hallmarks trial is the cleanest worked example of a nutrient combination measurably moving senescence-adjacent biomarkers in humans. See also the Supplements hub for the broader micronutrient context.

Grey areas — bleeding risk, EPA-only, and the ALA gap

Three things get under-discussed in the standard fish-oil narrative.

Bleeding risk is real at the doses the proteinuria trials used. The VITAL-DKD trial logged 28 gastrointestinal bleeding events on omega-3 versus 17 on placebo — at only 1 g/day². The Saglimbene meta showed a numeric excess in bleeding events (RR 1.40) that didn’t reach statistical significance but wasn’t reassuring either³. CKD patients tend to run on warfarin, DOACs, aspirin, or clopidogrel for cardiovascular indications. Stacking 2–4 g/day of omega-3 on top of those agents without clinician oversight is the kind of decision that ends with an avoidable bleed. This is the most underweighted trade-off in the consumer-fish-oil conversation.

EPA-only versus EPA+DHA is genuinely unresolved for kidney outcomes. The cardiovascular literature has split — REDUCE-IT showed event reduction with EPA-only icosapent ethyl while STRENGTH (a mixed EPA/DHA formulation) was null. No comparable head-to-head trial exists for kidney endpoints. The mechanism story doesn’t obviously favor one over the other — both serve as substrate for resolvin synthesis — but the trial data can’t answer the question yet. Default to balanced EPA+DHA from food and standard fish-oil supplements until the EPA-only kidney data arrives.

The ALA gap matters for non-fish-eaters. Plant ALA (flax, chia, walnut) converts to EPA at single-digit percent efficiency and to DHA at less than one percent. The BMJ pooled cohort analysis found no association between plant ALA biomarkers and incident CKD¹. For people who don’t eat fish and aren’t supplementing, plant ALA intake alone almost certainly doesn’t deliver the membrane EPA/DHA needed for resolvin biosynthesis. Algae-derived DHA + EPA supplements are the cleanest workaround for vegan and vegetarian readers.

What we don’t know yet

Several questions are open and worth flagging directly rather than dressing up:

Optimal dose for the senescence effect. The ORENTRA substudy used 2.6 g/day and moved SASP markers. The VITAL-DKD trial used 1 g/day and didn’t move eGFR. No published dose-response trial measures kidney senescence markers directly across a dose gradient in CKD.

Whether senescence-marker change translates to clinical outcome. The ORENTRA substudy moved circulating SASP markers; whether that translates to graft survival, reduced acute rejection, or slower long-term eGFR decline remains untested in an adequately powered trial.

Sex-specific effects. Most omega-3 CKD trials enrolled majority-male cohorts. Female-specific kidney aging biology — estrogen’s effects on glomerular hemodynamics, sex differences in senescence-marker accumulation — is largely unstudied in this context.

Pediatric and pregnancy gaps. Essentially no controlled omega-3 data exist for pediatric CKD or for kidney function during and after pregnancy. Both are populations where the senescence framing would predict a different effect from the dialysis-population framing.

Combination with senolytics. If omega-3 modulates SASP, the obvious next question is what happens when it’s combined with a senolytic agent that clears senescent cells outright. No human trial has tested this combination in any kidney population. The mechanism is compelling enough that one almost certainly should.

The honest summary: omega-3 is a reasonable foundational habit for general kidney health, modestly evidence-backed for proteinuria reduction in type 2 diabetic nephropathy at higher sustained doses, and an interesting but unresolved intervention in dialysis and transplant populations. It is not a treatment for established CKD. The senescence story finally explains why the trial data looked confused for thirty years — and points to the next round of trials that should actually measure what omega-3 is doing.

References

1. Ong KL, Marklund M, Huang L, et al. Association of omega 3 polyunsaturated fatty acids with incident chronic kidney disease: pooled analysis of 19 cohorts. BMJ. 2023;380:e072909. DOI
2. de Boer IH, Zelnick LR, Ruzinski J, et al. Effect of Vitamin D and Omega-3 Fatty Acid Supplementation on Kidney Function in Patients With Type 2 Diabetes: A Randomized Clinical Trial (VITAL-DKD). JAMA. 2019;322(19):1899–1909. DOI
3. Saglimbene VM, Wong G, van Zwieten A, et al. Effects of omega-3 polyunsaturated fatty acid intake in patients with chronic kidney disease: Systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2020;39(2):358–368. DOI
4. Chewcharat A, Chewcharat P, Rutirapong A, Papatheodorou S. The effects of omega-3 fatty acids on diabetic nephropathy: A meta-analysis of randomized controlled trials. PLoS ONE. 2020;15(2):e0228315. DOI
5. Hu J, Liu Z, Zhang H. Omega-3 fatty acid supplementation as an adjunctive therapy in the treatment of chronic kidney disease: a meta-analysis. Clinics. 2017;72(1):58–64. DOI
6. Chan JS, Kerr PG, Sammartino C, et al. Marine n-3 Polyunsaturated Fatty Acids and Cellular Senescence Markers in Incident Kidney Transplant Recipients: The Omega-3 Fatty Acids in Renal Transplantation (ORENTRA) Randomized Clinical Trial. Kidney Med. 2021;3(6):1041–1049. DOI
7. Li G, Wang Y, Chen Z, et al. Omega-3 polyunsaturated fatty acids alleviate renal fibrosis in chronic kidney disease by reducing macrophage activation and infiltration through the JAG1-NOTCH1/2 pathway. Int Immunopharmacol. 2025;143:114156. DOI
8. Hong SP, Wen J, Bang S, et al. Omega-3 fatty acid-derived resolvins and protectins in inflammation resolution and leukocyte functions: targeting novel lipid mediator pathways in mitigation of acute kidney injury. Front Immunol. 2013;4:13. DOI
9. Rex N, Melk A, Schmitt R. Cellular senescence and kidney aging. Clin Sci (Lond). 2023;137(24):1805–1821. DOI
10. Fazelian S, Moradi F, Agah S, et al. Effect of omega-3 fatty acids supplementation on cardio-metabolic and oxidative stress parameters in patients with chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2021;22(1):160. DOI
11. Phillips PCA, Sangwung P, Ahmed I, et al. Targeting senescence to prevent diabetic kidney disease: Exploring molecular mechanisms and potential therapeutic targets for disease management. Diabet Med. 2024;41(8):e15408. DOI